EMERSON PERIN to Ventricular Function, Left
This is a "connection" page, showing publications EMERSON PERIN has written about Ventricular Function, Left.
Connection Strength
1.420
-
The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. Catheter Cardiovasc Interv. 2017 Feb 01; 89(2):169-177.
Score: 0.409
-
Randomized Trial of Targeted Transendocardial Mesenchymal Precursor?Cell Therapy in Patients With?Heart?Failure. J Am Coll Cardiol. 2023 03 07; 81(9):849-863.
Score: 0.160
-
Left ventricular electromechanical mapping: preliminary evidence of electromechanical changes after successful coronary intervention. Am Heart J. 2002 Oct; 144(4):693-701.
Score: 0.155
-
Left ventricular electromechanical mapping: a case study of functional assessment in coronary intervention. Tex Heart Inst J. 2000; 27(3):253-6.
Score: 0.128
-
Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial. Am Heart J. 2018 07; 201:54-62.
Score: 0.114
-
Association between High Endocardial Unipolar Voltage and Improved Left Ventricular Function in Patients with Ischemic Cardiomyopathy. Tex Heart Inst J. 2016 Aug; 43(4):291-6.
Score: 0.101
-
Safety and feasibility of mapping and stem cell delivery in the presence of an implanted left ventricular assist device: a preclinical investigation in sheep. Tex Heart Inst J. 2013; 40(3):229-34.
Score: 0.079
-
Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011 Nov 16; 306(19):2110-9.
Score: 0.073
-
Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003 May 13; 107(18):2294-302.
Score: 0.040
-
A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. Eur J Heart Fail. 2021 04; 23(4):661-674.
Score: 0.035
-
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial. Am Heart J. 2016 09; 179:142-50.
Score: 0.025
-
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial. Cell Transplant. 2016; 25(9):1675-1687.
Score: 0.024
-
Cardiac sarcoidosis. An unusual form of acute congestive cardiomyopathy. Tex Heart Inst J. 1995; 22(3):265-7.
Score: 0.023
-
Determinants and outcomes of asystole during carotid artery stenting. J Endovasc Ther. 2011 Aug; 18(4):513-7.
Score: 0.018
-
Characterization of mechanical dyssynchrony measured by gated single photon emission computed tomography phase analysis after acute ST-elevation myocardial infarction. J Nucl Cardiol. 2011 Oct; 18(5):912-9.
Score: 0.018
-
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010; 37(4):412-20.
Score: 0.016